CTRI/2022/04/041602Recruiting未知
An open label, multi-center, randomized, two-treatment, three-period, three-sequence, single-dose, reference replicate, pharmacokinetic bioequivalence study of Leuprolide Depot Injection 7.5 mg of American Regent, Inc. with LUPRON Depot (leuprolide acetate for depot suspension) 7.5 mg of AbbVieInc. North Chicago, IL 60064 in adult male subjects with locally advanced and/or metastatic prostate cancer undergoing initial therapy. - NA
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- American Regent Inc
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Subjects will be considered eligible for the study based on the following criteria:
- •1. Willing and able to provide voluntary informed consent prior commencement of any study-related activities, and the ability to follow protocol requirements
- •2. Male subjects aged 18 to 75 years (both inclusive) with body mass index (BMI) between 18.00 to 30.00 kg per m2 (both inclusive)
- •3. Males with histologically or cytologically confirmed carcinoma of the prostate
- •4. Subjects, newly diagnosed locally advanced and/or metastatic prostate cancer, scheduled to receive their first dose of leuprolide acetate as a part of their standard of care
- •5. Eastern Cooperative Oncology Group (ECOG) performance status Less than or equal to 2.
- •6. Acceptable hematology status:
- •a. Hemoglobin Greater than or equal to 9 g pe dL
- •b. Absolute neutrophil count (ANC) Greater than or equal to 1500 cells per mm3
- •c. Platelet count Greater than or equal to 100,000 cells/mm3
- •7. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) Less than or equal to 2 X ULN
- •b. Aspartate aminotransferase (AST) Less than or equal to 2 X ULN
- •c. Bilirubin Less than or equal to 1.2 mg per dL
- •d. Alkaline phosphatase Less than or equal to 5 x ULN
- •8. Subjects with HbA1c Less than or equal to 7 %
- •9. Subjects with life expectancy of at least 6 (six) months at the time of enrolment
- •10. Young adult subjects who wish to bank their semen must agree for semen banking prior to 24 hours of receiving the first dose of Investigational Product
- •11. Subjects who agree to use adequate male contraceptive methods while in the study
- •12. No history of addiction to any recreational drug or drug dependence or alcohol addiction within 12 months before screening
Exclusion Criteria
- •Subjects will be excluded from the study based on the following criteria:
- •1. Known hypersensitivity or contraindication to gonadotropin-releasing hormone(GnRH), GnRH agonist or to any of the components of investigational product
- •2. Prior orchidectomy, hypophysectomy or adrenalectomy
- •3. Clinical indication of urinary tract obstruction
- •4. History of any major surgical procedure (including periodontal) within 28 days of dose of investigational product
- •5. Corrected QT interval [Bazetts formula (QTcB)] Greater than 450 msec at screening
- •6. History or presence of any uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.)
- •7. Known CNS metastasis
- •8. Surgical or other non-healing wounds
- •9. Subjects with positive serology for Hepatitis B virus (HBV), Hepatitis C virus (HCV),or Human immunodeficiency virus (HIV)
- •10. Subject with history or presence of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumours or subjects who are on concomitant medications that have been associated with convulsions such as bupropion and Selective serotonin reuptake inhibitors (SSRIs)
- •11. Subjects with positive urine screen for drugs of abuse on day 0
- •12. Subjects with positive urine alcohol test on day 0
- •13. Smokers who smoke Greater than or equal to 10 cigarettes or equivalent per week
- •14. History of other malignancies in the last 5 years (except in situ cancer or basal or squamous cell skin cancer)
- •15. Have not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable),hemoglobin Greater than or equal to 9 g per dL, fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V 5.0)
- •16. Participation in any clinical study 90 days prior to receiving the investigational product (IP) of the current study
- •17. Loss of Greater than or equal to 350 mL blood 90 days prior to receiving the IP of the current study
- •18. Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study, including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements
- •19. Subjects with confirmed novel coronavirus infection (COVID-19) or subjects who have taken COVID-19 vaccine within 4 weeks prior to dosing
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Bioequivalence (BE) study of Paclitaxel 100mg/vial with ABRAXANE® 100mg/vial in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.CTRI/2024/03/064383Anbison Lab. Co., Ltd.
Not yet recruiting
Not Applicable
Bioequivalence study of doxorubicin hydrochloride liposome injection 2mg/mL in ovarian cancer subjects under fasting conditions.CTRI/2020/05/025245Shanghai Jingfeng Pharmaceuticals Group Co Ltd China
Recruiting
Phase 1
Bioavailability study between Bortezomib for Injection 3.5 mg/0.2 mL and VELCADE 3.5 mg powder for solution for injection at a dose of 1.3 mg/m2CTRI/2020/06/025971Shilpa Medicare Limited
Completed
Not Applicable
Bioavailability study of Bortezomib for Injection 3.5 mg/vial in patients with Multiple MyelomaCTRI/2019/03/018107Shilpa Medicare Limited6
Completed
Not Applicable
A comparative study of Doxorubicin Hydrochloride in ovarian and/or breast cancer patients.CTRI/2017/07/009118Dr Reddys Laboratories Ltd85